Is alpha-L-Iduronide iduronohydrolase Safe in Breastfeeding
Question
I am a breastfeeding mother and i want to know if it is safe to use alpha-L-Iduronide iduronohydrolase? Is alpha-L-Iduronide iduronohydrolase safe for nursing mother and child? Does alpha-L-Iduronide iduronohydrolase extracts into breast milk? Does alpha-L-Iduronide iduronohydrolase has any long term or short term side effects on infants? Can alpha-L-Iduronide iduronohydrolase influence milk supply or can alpha-L-Iduronide iduronohydrolase decrease milk supply in lactating mothers?
alpha-L-Iduronide iduronohydrolase lactation summary
- DrLact safety Score for alpha-L-Iduronide iduronohydrolase is 3 out of 8 which is considered Low Risk as per our analyses.
- A safety Score of 3 indicates that usage of alpha-L-Iduronide iduronohydrolase may cause some minor side effects in breastfed baby.
- Our study of different scientific research indicates that alpha-L-Iduronide iduronohydrolase may cause moderate to no side effects in lactating mother.
- Most of scientific studies and research papers declaring usage of alpha-L-Iduronide iduronohydrolase low risk in breastfeeding are based on normal dosage and may not hold true for higher dosage.
- While using alpha-L-Iduronide iduronohydrolase We suggest monitoring child for possible reactions. It is also important to understand that side effects vary largely based on age of breastfed child and time of medication in addition to dosage.
- Score calculated using the DrLact safety Version 1.2 model, this score ranges from 0 to 8 and measures overall safety of drug in lactation. Scores are primarily calculated using publicly available case studies, research papers, other scientific journals and publically available data.
Answer by Dr. Ru: About alpha-L-Iduronide iduronohydrolase usage in lactation
Recombinant-type of alfa-L-iduronidase that is used in enzyme replacement therapy in patients with Mucopolysaccharidosis I (MPS I). Its high molecular weight explains the null passage observed in the milk of a nursing mother who had received weekly doses of Laronidase for three months, while she was breastfeeding. No physical or developmental problems in infants in the short or long term were observed. Its low oral bioavailability hampers its passage from the breast milk ingested to the infant's plasma since it is degraded in the gastrointestinal tract due to its proteinaceous nature. It is not absorbed by the gut except in the immediate neonatal period or prematurity when intestinal permeability may be increased. Weekly administration and short half life span allows, if desired, developing strategies to further minimize the risk of exposure (e.g. avoid breastfeeding between 4 and 8 hours after receiving a dose, using the "pump and dump method" of the breast milk while the baby is fed with previously extracted milk)